Brief: Tiziana Life Sciences Announces Reduction In Microglial Activation In A Total Of 5 Out Of 6 Intranasal Foralumab Expanded Access Patients With Non-Active Secondary Progressive Multiple Sclerosis
05/06/2023 15:33
June 5 (Reuters) - Tiziana Life Sciences Ltd TLSA.O :
* TIZIANA LIFE SCIENCES ANNOUNCES REDUCTION IN MICROGLIAL
ACTIVATION IN A TOTAL OF 5 OUT OF 6 INTRANASAL FORALUMAB
EXPANDED ACCESS PATIENTS WITH NON-ACTIVE SECONDARY PROGRESSIVE
MULTIPLE SCLEROSIS
* TIZIANA LIFE SCIENCES LTD - PHASE 2A TRIAL IN NA-SPMS ON
TRACK
TO BEGIN IN Q3 2023
Source text for Eikon: ID:nGNX9qQt3W
Further company coverage: TLSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tiziana Life Sciences
See all newsBrief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis
U.S. STOCKS ON THE MOVE -Viatris, Clear Secure, Bicara
U.S. STOCKS ON THE MOVE-Sharps Technology, Whirlpool, Applovin
U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight
Tiziana Life Sciences rises as nasal MS drug shows promise in early study